HRP20120093T1 - Postojani pripravci lakvinimoda - Google Patents

Postojani pripravci lakvinimoda Download PDF

Info

Publication number
HRP20120093T1
HRP20120093T1 HR20120093T HRP20120093T HRP20120093T1 HR P20120093 T1 HRP20120093 T1 HR P20120093T1 HR 20120093 T HR20120093 T HR 20120093T HR P20120093 T HRP20120093 T HR P20120093T HR P20120093 T1 HRP20120093 T1 HR P20120093T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
oxoquinoline
carboxamide
dihydro
Prior art date
Application number
HR20120093T
Other languages
English (en)
Croatian (hr)
Inventor
Patashnik Shulamit
Licht Daniella
Gilbert Adrian
Original Assignee
Teva Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Limited filed Critical Teva Pharmaceutical Industries Limited
Publication of HRP20120093T1 publication Critical patent/HRP20120093T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Composite Materials (AREA)
  • Mechanical Engineering (AREA)
HR20120093T 2006-06-12 2007-06-12 Postojani pripravci lakvinimoda HRP20120093T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81324706P 2006-06-12 2006-06-12
PCT/US2007/013721 WO2007146248A2 (fr) 2006-06-12 2007-06-12 Préparations de laquinimod stables

Publications (1)

Publication Number Publication Date
HRP20120093T1 true HRP20120093T1 (hr) 2012-03-31

Family

ID=38832466

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120093T HRP20120093T1 (hr) 2006-06-12 2007-06-12 Postojani pripravci lakvinimoda

Country Status (27)

Country Link
US (3) US7989473B2 (fr)
EP (1) EP2035001B1 (fr)
JP (1) JP5226678B2 (fr)
KR (4) KR20150065951A (fr)
CN (1) CN101466379B (fr)
AR (1) AR061348A1 (fr)
AT (1) ATE532515T1 (fr)
AU (1) AU2007258366B2 (fr)
BR (1) BRPI0713694A2 (fr)
CA (2) CA2899472C (fr)
CY (1) CY1113003T1 (fr)
DK (1) DK2035001T3 (fr)
EA (1) EA018031B1 (fr)
ES (1) ES2377149T3 (fr)
HR (1) HRP20120093T1 (fr)
IL (1) IL195724A (fr)
MX (1) MX2008015808A (fr)
NO (1) NO342485B1 (fr)
NZ (1) NZ573846A (fr)
PL (1) PL2035001T3 (fr)
PT (1) PT2035001E (fr)
RS (1) RS52169B (fr)
SI (1) SI2035001T1 (fr)
TW (1) TWI400073B (fr)
UA (1) UA96449C2 (fr)
WO (1) WO2007146248A2 (fr)
ZA (1) ZA200810790B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SG10201508623RA (en) 2005-10-19 2015-11-27 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
KR20150065951A (ko) 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
WO2009082471A1 (fr) * 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Préparations de laquinimod stables
MX2011002033A (es) * 2008-09-03 2011-05-02 Teva Pharma 2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
EP2442651B1 (fr) * 2009-06-19 2015-07-29 Teva Pharmaceutical Industries Ltd. Traitement de la sclérose en plaques par le laquinimod
ES2564931T3 (es) * 2009-07-30 2016-03-30 Teva Pharmaceutical Industries Ltd. Tratamiento de enfermedad de Crohn con laquinimod
CA2771203C (fr) * 2009-08-10 2019-04-09 Teva Pharmaceutical Industries Ltd. Traitement de troubles lies au fndc au moyen de laquinimod
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
WO2011109526A1 (fr) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Traitement de la néphrite de lupus à l'aide du laquinimod
MX2012010066A (es) * 2010-03-03 2012-10-03 Teva Pharma Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato.
US20110217295A1 (en) * 2010-03-03 2011-09-08 Asi Haviv Treatment of lupus arthritis using laquinimod
CN104610144A (zh) 2010-07-09 2015-05-13 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
EA201390074A1 (ru) * 2010-07-09 2013-06-28 Тева Фармасьютикал Индастриз Лтд. 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения
CA2820586A1 (fr) * 2010-12-07 2012-06-14 Teva Pharmaceutical Industries Ltd. Utilisation de laquinimod pour la reduction de la fatigue, l'amelioration de l'etat fonctionnel, et l'amelioration de la qualite de vie chez des patients atteints de sclerose en plaques
SG10201606204TA (en) * 2011-07-28 2016-09-29 Teva Pharma Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta
CN103781354A (zh) * 2011-07-28 2014-05-07 泰华制药工业有限公司 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
EP2766020A4 (fr) * 2011-10-12 2015-04-01 Teva Pharma Traitement de la sclérose en plaques par combinaison de laquinimod et de fingolimod
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
WO2014004733A1 (fr) * 2012-06-26 2014-01-03 The Regents Of The University Of California Composition pour la néphropathie lupique et ses méthodes de fabrication et d'utilisation
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
TW201410243A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
MX2015005632A (es) * 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
WO2014127139A1 (fr) * 2013-02-15 2014-08-21 Teva Pharmaceutical Industries Ltd. Traitement de la sclérose en plaques à l'aide de laquinimod
EP2970129A2 (fr) * 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Cristaux de sodium de laquinimod et procédé amélioré pour leur fabrication
MX2015010967A (es) 2013-03-14 2015-10-26 Teva Pharma Formulaciones transdermicas de laquinimod.
AU2014342917A1 (en) * 2013-09-27 2016-04-21 Teva Pharmaceutical Industries Ltd. Laquinimod combination therapy for treatment of multiple sclerosis
TW201609098A (zh) * 2013-12-20 2016-03-16 泰瓦藥品工業有限公司 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途
EP3094330A4 (fr) * 2014-01-17 2017-09-27 Teva Pharmaceutical Industries Ltd Traitement de la maladie de crohn au moyen de faibles doses de laquinimod
KR20170005434A (ko) 2014-04-29 2017-01-13 테바 파마슈티컬 인더스트리즈 리미티드 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드
CN110193014B (zh) * 2019-06-06 2021-05-11 温州医科大学 一种注射用拉喹莫德胶束冻干制剂及制备方法、拉喹莫德注射制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3024257A (en) * 1961-04-10 1962-03-06 Frosst & Co Charles E Stable preparations of alkali metal salts of estrone sulfate
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
CH687615A5 (de) * 1994-09-07 1997-01-15 R W Johnson Pharmaceutical Res Tropen-Verpackung.
US5912349A (en) 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
JP4980527B2 (ja) 1999-06-07 2012-07-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性化合物を含有する新規の製剤および投与形
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
PL199781B1 (pl) 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
JP2002031610A (ja) 2000-07-14 2002-01-31 Ajinomoto Co Inc 生体分子複合体の界面残基を同定する方法
US6307050B1 (en) 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6802422B2 (en) * 2000-12-12 2004-10-12 Multi-Comp, Inc. Sealed blister assembly
US6706733B2 (en) 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US20030119826A1 (en) * 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
AU2003300692A1 (en) * 2003-10-30 2005-05-19 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SG10201508623RA (en) 2005-10-19 2015-11-27 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
KR20150065951A (ko) 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
US20080087929A1 (en) * 2006-10-11 2008-04-17 Infineon Technologies Ag Static random access memory with thin oxide capacitor
WO2009082471A1 (fr) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Préparations de laquinimod stables
MX2011002033A (es) 2008-09-03 2011-05-02 Teva Pharma 2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
EP2442651B1 (fr) 2009-06-19 2015-07-29 Teva Pharmaceutical Industries Ltd. Traitement de la sclérose en plaques par le laquinimod
ES2564931T3 (es) 2009-07-30 2016-03-30 Teva Pharmaceutical Industries Ltd. Tratamiento de enfermedad de Crohn con laquinimod
CA2771203C (fr) 2009-08-10 2019-04-09 Teva Pharmaceutical Industries Ltd. Traitement de troubles lies au fndc au moyen de laquinimod
MX2012010066A (es) 2010-03-03 2012-10-03 Teva Pharma Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato.
US20110217295A1 (en) 2010-03-03 2011-09-08 Asi Haviv Treatment of lupus arthritis using laquinimod
WO2011109526A1 (fr) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Traitement de la néphrite de lupus à l'aide du laquinimod
EA201390074A1 (ru) 2010-07-09 2013-06-28 Тева Фармасьютикал Индастриз Лтд. 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения
CN104610144A (zh) 2010-07-09 2015-05-13 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途

Also Published As

Publication number Publication date
JP2009539984A (ja) 2009-11-19
US20110251235A1 (en) 2011-10-13
ES2377149T3 (es) 2012-03-22
EP2035001A2 (fr) 2009-03-18
KR20150065951A (ko) 2015-06-15
MX2008015808A (es) 2009-02-17
AU2007258366B2 (en) 2012-10-25
WO2007146248A2 (fr) 2007-12-21
DK2035001T3 (da) 2012-02-27
NO20090175L (no) 2009-03-11
WO2007146248A3 (fr) 2008-12-24
SI2035001T1 (sl) 2012-03-30
UA96449C2 (en) 2011-11-10
KR20140091778A (ko) 2014-07-22
KR20160013273A (ko) 2016-02-03
US20070293537A1 (en) 2007-12-20
IL195724A0 (en) 2009-09-01
NZ573846A (en) 2012-01-12
RS52169B (sr) 2012-08-31
CN101466379A (zh) 2009-06-24
AR061348A1 (es) 2008-08-20
PT2035001E (pt) 2012-02-06
US7989473B2 (en) 2011-08-02
CA2899472C (fr) 2019-04-30
PL2035001T3 (pl) 2012-05-31
TW200815006A (en) 2008-04-01
AU2007258366A1 (en) 2007-12-21
IL195724A (en) 2015-09-24
US8383645B2 (en) 2013-02-26
EA200870599A1 (ru) 2009-06-30
CA2654982C (fr) 2015-11-10
HK1121971A1 (en) 2009-05-08
NO342485B1 (no) 2018-05-28
US20120302600A1 (en) 2012-11-29
KR20090017694A (ko) 2009-02-18
CA2899472A1 (fr) 2007-12-21
JP5226678B2 (ja) 2013-07-03
CA2654982A1 (fr) 2007-12-21
EP2035001A4 (fr) 2009-09-23
ZA200810790B (en) 2010-03-31
KR101495327B1 (ko) 2015-02-24
CN101466379B (zh) 2012-10-31
CY1113003T1 (el) 2016-04-13
ATE532515T1 (de) 2011-11-15
EP2035001B1 (fr) 2011-11-09
BRPI0713694A2 (pt) 2012-10-30
TWI400073B (zh) 2013-07-01
EA018031B1 (ru) 2013-05-30

Similar Documents

Publication Publication Date Title
EP0973557B1 (fr) Compositions et procedes de conservation de verres de contact
JP2009539984A5 (fr)
HRP20210487T1 (hr) Farmaceutski sastavi koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo
AR063471A1 (es) Formulaciones para administracion parenteral de compuestos y sus usos
HRP20240004T1 (hr) Formulacije agonista guanilat ciklaze c i postupci uporabe
AR043863A1 (es) Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines
HRP20010243B1 (hr) Pripravci koji sadrže difosfonske kiseline
RU2009127336A (ru) Композиции для ухода за полостью рта, содержащие полифосфат
TN2009000197A1 (en) Sustained - release composition and method for producing the same
HRP20110162A8 (hr) Spojevi koji sadrže amlodipin i bisoprolol
JP2019218395A (ja) 眼科用組成物
ITMI990834A1 (it) Cerotto per uso topico eparina e diclofenac
EA201500376A1 (ru) Композиция для ухода за полостью рта
TW372193B (en) Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient
EA201170784A1 (ru) Гранулы тамсулозина для фиксированной комбинации
JP2016522257A5 (fr)
CA2573985C (fr) Composition pharmaceutique comprenant de la gabapentine
ATE412404T1 (de) Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon
RU2015141639A (ru) Комбинированный лекарственный препарат в форме шипучих таблеток и способ его получения
JP2002258223A (ja) 眼科用組成物
KR20140001648A (ko) 안정성이 개선된 클로피도그렐 황산수소염의 경구용 제제 제품
ES2202318T3 (es) Compuesto que contiene complejos de aluminio para el tratamiento de quemaduras termicaso o quimicas.
MX2023012827A (es) Producto oral en bolsa de múltiples compartimentos.
CA2903289A1 (fr) Preservatif
HRP20030057A2 (en) Antiseptic for wounds and mucous membranes